[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.197.114. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Clinical Note
November 2004

Intralesional Cidofovir for Pediatric Recurrent Respiratory Papillomatosis

Arch Otolaryngol Head Neck Surg. 2004;130(11):1319-1323. doi:10.1001/archotol.130.11.1319
Abstract

Objective  To compare disease response among children with recurrent respiratory papillomatosis (RRP) who underwent combined surgical debulking and intralesional cidofovir injections vs repeated surgical debulking only.

Design  Retrospective medical record review; follow-up range: 16 to 56 months.

Setting  Tertiary care children’s hospital.

Patients  Seven children with RRP, including 4 subjects treated with cidofovir and 3 controls matched for age and initial papilloma staging score.

Interventions  Subjects treated with cidofovir underwent combined surgical debulking and intralesional cidofovir injection every 2 months until disease remission. Control subjects underwent repeated surgical debulking at individually determined intervals.

Main Outcome Measures  Intraoperative endoscopic photographs were retrospectively assigned papilloma staging scores. Cidofovir and control group comparisons were made using nonparametric 2-sample Wilcoxon rank-sum (Mann-Whitney) testing, and comparisons of initial and final papilloma staging scores were made using nonparametric matched-pair Wilcoxon signed-rank testing.

Results  The final cidofovir group scores were significantly lower than the control group scores (P < .05). Within-group differences between initial and final scores were not significant (cidofovir group, P = .07; control group, P = .29).

Conclusions  Four children with RRP were safely and successfully treated with intralesional cidofovir injection. Consideration should be given to using cidofovir more widely for treatment of pediatric RRP. Larger numbers in the cidofovir and control groups are needed in future studies to determine the true impact of cidofovir on management of this disease.

×